CDH1 and gastric cancer: Bougen-Zhukov et al. reported that E-cadherin-deficient cells are sensitive to the multikinase inhibitor dasatinib, suggesting that targeting specific signaling pathways could provide therapeutic benefits for patients with gastric cancer characterized by low E-cadherin expression [78].